America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy‘.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research for the treatment of breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What are the advantages of targeted chemotherapy drugs like AOH1996 over traditional chemotherapy options?
**Interview with Dr. Linda Malkas, Lead Researcher on Targeted Chemotherapy Drug AOH1996**
**Interviewer:** Dr. Malkas, thank you for joining us today! Your team’s recent developments at City of Hope have caught significant attention. Can you explain what makes AOH1996 so unique compared to traditional chemotherapy treatments?
**Dr. Malkas:** Thank you for having me! AOH1996 is unique because it uses targeted chemotherapy to specifically disrupt cancer cells while sparing healthy ones. We liken our mechanism to a blizzard that can effectively shut down only the planes that are carrying cancer cells, leaving the rest of the system unaffected. This is achieved by targeting a specific variant of the PCNA protein, which is crucial for DNA replication and tumor growth in cancer cells.
**Interviewer:** That’s an intriguing analogy! Can you tell us more about the research process you went through to develop this drug?
**Dr. Malkas:** Absolutely. The research process spanned over two decades, during which we studied the molecular pathways involved in cancer cell proliferation. We tested AOH1996 on more than 70 cancer cell lines in our studies, which were published in *Cell Chemical Biology*. The results were promising as we observed that AOH1996 selectively kills cancer cells by interfering with their reproductive cycle.
**Interviewer:** What types of cancers does AOH1996 potentially target, and what has been the feedback from initial clinical trials?
**Dr. Malkas:** AOH1996 has shown effectiveness against several types of cancer, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. The feedback from preliminary trials has been very encouraging, and we’re optimistic about advancing these findings through further clinical trials in humans, which is the next crucial step.
**Interviewer:** That sounds very promising for cancer patients. When can we expect to see this drug available for broader therapeutic use?
**Dr. Malkas:** While it’s still early, we are dedicated to expediting the upcoming clinical trials. Our goal is to ensure that all necessary safety and efficacy evaluations are met before it can become widely available for patients. Patience is essential as we navigate through this rigorous process, but we are hopeful for positive outcomes.
**Interviewer:** Thank you, Dr. Malkas. Your work holds great potential for transforming cancer treatment, and we look forward to hearing more about AOH1996 in the future!
**Dr. Malkas:** Thank you for the opportunity to share our work. I appreciate your interest!